Seeking Alpha

Repros Therapeutics jumps as Androxal meets endpoints

  • Repros Therapeutics (RPRX) soars 26% premarket.
  • Androxal topline results from ZA-302 (pivotal efficacy) and ZA-300 (six-month safety) show the secondary hypogonadism treatment met both primary endpoints and is generally well tolerated.
  • ZA-302 results are "almost identical" to the first pivotal efficacy study. (PR)
  • Expect an NDA in mid-2014.
  • RPRX says it expects to have "launch drug product available for an anticipated approval during 2015."
  • It's worth noting that back in July, BofA's Steve Byrne said peak 2022 sales could reach $450M.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs